Roles of transforming growth factor-β signaling in liver disease

IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY
Xiaoling Wang, Meng Yang, Ying Wang
{"title":"Roles of transforming growth factor-β signaling in liver disease","authors":"Xiaoling Wang, Meng Yang, Ying Wang","doi":"10.4254/wjh.v16.i7.973","DOIUrl":null,"url":null,"abstract":"In this editorial we expand the discussion on the article by Zhang et al published in the recent issue of the World Journal of Hepatology . We focus on the diagnostic and therapeutic targets identified on the basis of the current understanding of the molecular mechanisms of liver disease. Transforming growth factor-β (TGF-β) belongs to a structurally related cytokine super family. The family members display different time- and tissue-specific expression patterns associated with autoimmunity, inflammation, fibrosis, and tumorigenesis; and, they participate in the pathogenesis of many diseases. TGF-β and its related signaling pathways have been shown to participate in the progression of liver diseases, such as injury, inflammation, fibrosis, cirrhosis, and cancer. The often studied TGF-β/Smad signaling pathway has been shown to promote or inhibit liver fibrosis under different circumstances. Similarly, the early immature TGF-β molecule functions as a tumor suppressor, inducing apoptosis; but, its interaction with the mitogenic molecule epidermal growth factor alters this effect, activating anti-apoptotic signals that promote liver cancer development. Overall, TGF-β signaling displays contradictory effects in different liver disease stages. Therefore, the use of TGF-β and related signaling pathway molecules for diagnosis and treatment of liver diseases remains a challenge and needs further study. In this editorial, we aim to review the evidence for the use of TGF-β signaling pathway molecules as diagnostic or therapeutic targets for different liver disease stages.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4254/wjh.v16.i7.973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In this editorial we expand the discussion on the article by Zhang et al published in the recent issue of the World Journal of Hepatology . We focus on the diagnostic and therapeutic targets identified on the basis of the current understanding of the molecular mechanisms of liver disease. Transforming growth factor-β (TGF-β) belongs to a structurally related cytokine super family. The family members display different time- and tissue-specific expression patterns associated with autoimmunity, inflammation, fibrosis, and tumorigenesis; and, they participate in the pathogenesis of many diseases. TGF-β and its related signaling pathways have been shown to participate in the progression of liver diseases, such as injury, inflammation, fibrosis, cirrhosis, and cancer. The often studied TGF-β/Smad signaling pathway has been shown to promote or inhibit liver fibrosis under different circumstances. Similarly, the early immature TGF-β molecule functions as a tumor suppressor, inducing apoptosis; but, its interaction with the mitogenic molecule epidermal growth factor alters this effect, activating anti-apoptotic signals that promote liver cancer development. Overall, TGF-β signaling displays contradictory effects in different liver disease stages. Therefore, the use of TGF-β and related signaling pathway molecules for diagnosis and treatment of liver diseases remains a challenge and needs further study. In this editorial, we aim to review the evidence for the use of TGF-β signaling pathway molecules as diagnostic or therapeutic targets for different liver disease stages.
转化生长因子-β 信号在肝病中的作用
在这篇社论中,我们将进一步讨论 Zhang 等人发表在最近一期《世界肝脏病学杂志》上的文章。我们将重点讨论根据目前对肝病分子机制的理解而确定的诊断和治疗靶点。转化生长因子-β(TGF-β)属于结构相关的细胞因子超家族。该家族成员在自身免疫、炎症、纤维化和肿瘤发生过程中表现出不同的时间和组织特异性表达模式,并参与多种疾病的发病机制。研究表明,TGF-β 及其相关信号通路参与了肝脏疾病的进展,如损伤、炎症、纤维化、肝硬化和癌症。经常被研究的 TGF-β/Smad 信号通路已被证明在不同情况下可促进或抑制肝纤维化。同样,早期未成熟的 TGF-β 分子具有肿瘤抑制功能,可诱导细胞凋亡;但它与有丝分裂分子表皮生长因子的相互作用改变了这种效应,激活了促进肝癌发展的抗凋亡信号。总之,TGF-β 信号在肝病的不同阶段显示出相互矛盾的作用。因此,利用 TGF-β 及相关信号通路分子诊断和治疗肝病仍是一项挑战,需要进一步研究。在这篇社论中,我们旨在回顾将 TGF-β 信号通路分子作为不同肝病阶段的诊断或治疗靶点的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Hepatology
World Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.10
自引率
4.20%
发文量
172
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信